louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00680082: Observational Usage Study of Statins in Primary Care in France
Official title: Observational Usage Study of Statins in Primary Care in France
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Keywords: statins
rosuvastatin
cross sectional study
France
CV risk factors
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-05-19
Enrollment: 2100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patients recruited by a GP, community sample

Brief summary: To describe the way statins are used in France in primary care, that is to determine patients profile (particularly CV risk factors), to determine the way statins are initiated by general practitioners, to evaluate aftercare and to assess patients treated by rosuvastatin


Eligibility criteria: Inclusion Criteria:

* Patients to whom a statin was initiated or switched between 3 and 6 months before consultation

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Hefei
country: China
facility: Research Site
state: Anhui
city: Chongqing
country: China
facility: Research Site
state: Chongqing
city: Fuzhou
country: China
facility: Research Site
state: Fujian
city: Guangzhou
country: China
facility: Research Site
state: Guangdong
city: Shenzhen
country: China
facility: Research Site
state: Guangdong
city: Xiamen
country: China
facility: Research Site
state: Guangdong
city: Zhongshan
country: China
facility: Research Site
state: Guangdong
city: Zhengzhou
country: China
facility: Research Site
state: Henan
city: Wuhan
country: China
facility: Research Site
state: Hubei
city: Changsha
country: China
facility: Research Site
state: Hunan
city: Nanjing
country: China
facility: Research Site
state: Jiangsu
city: Suzhou
country: China
facility: Research Site
state: Jiangsu
city: Wuxi
country: China
facility: Research Site
state: Jiangsu
city: Nanchang
country: China
facility: Research Site
state: Jiangxi
city: Jinan
country: China
facility: Research Site
state: Shandong
city: Qingdao
country: China
facility: Research Site
state: Shandong
city: Shanghai
country: China
facility: Research Site
state: Shanghai
city: Taiyuan
country: China
facility: Research Site
state: Shanxi
city: Xi'an
country: China
facility: Research Site
state: Shanxi
city: Chengdu
country: China
facility: Research Site
state: Sichuan
city: Kunming
country: China
facility: Research Site
state: Yunnan
city: Hangzhou
country: China
facility: Research Site
state: Zhejiang
city: Ningbo
country: China
facility: Research Site
state: Zhejiang
city: Rui'an
country: China
facility: Research Site
state: Zhejiang
city: Wenzhou
country: China
facility: Research Site
state: Zhejiang
Study officials:
affiliation: Cegedim Strategic Data - Boulogne Billancourt - France
name: Francois Morand
role: PRINCIPAL_INVESTIGATOR
affiliation: Institut Pasteur - Inserm U744 - Lille -France
name: Jean Dallongeville
role: STUDY_CHAIR
References:
Clinical trial NCT03488082: MRI Study of Saccadic Adaptation
Official title: Coupling Between Saccadic Adaptation and Visuospatial Perception Process: MRI Study in Humans
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Volunteers
Keywords: saccadic adaptation
visual-spatial perception
fMRI
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2018-04-04
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Accurate execution of our directed behaviors in the immediate environment allows the vast majority of our daily activities. Through the movements of our eyes and different parts of our body, we perceive, explore and act on our environment and can exchange and communicate with others. The mechanisms of sensorimotor adaptation of saccades (saccadic adaptation) contribute on the one hand to maintain the accuracy of saccades in the short, medium and long term, by opposing the deleterious effects of various physiological changes (development, aging), pathological or environmental (optical corrections).

The aim of this study is to identify neuronal structures and networks involved in saccadic adaptation through the study of brain metabolic activation (BOLD) during the development of the adaptation of reactive saccades. The study will be organized in a single session with 3 runs. Each run include 4 blocks: 3 include the double-step target paradigm RND, U+, U-) and one without target jump (STA). The 'U+'/ 'U-'blocks include saccadic trials with forward/backward displacement of the target during a targeting saccade, the 'RND' block include saccadic trials with random target jump (forward or backward) and the 'STA' block are trials without displacement of the target. Each subject will make 12 repetitions of the 4 blocks.


Eligibility criteria: Inclusion Criteria:

- Age: 18 to 40 years included,

Exclusion Criteria:

* Known ophthalmological or neurological pathology,
* Non-stabilized medical condition,
* Taking psychotropic treatment,
* No fluency in reading in French,
* Pregnant and / or breastfeeding woman

Primary outcomes:
measure: BOLD signal
timeFrame: throughout the behavioral experiment at Day 1
Secondary outcomes:
measure: Eye movements
timeFrame: during the development of saccadic adaptation (throughout the behavioral experiments at Day 1)
Other outcomes:
Locations:
city: Bron
country: France
facility: Inserm U1208
Study officials:
affiliation: INSERM U1208
name: Denis PELISSON
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00495482: Incurable Ill Patients Attitudes Towards Euthanasia and Assisted Suicide
Official title: Incurable Ill Patients Attitudes to Euthanasia and Assisted Suicide: A Prospective, Multi-Centre Trial in Palliative Care Units in Saxony
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Incurable Cancer Diseases
Other Incurable Diseases
Keywords: Euthanasia
Assisted Suicide
Assisted Dying
Palliative Care Medicine
Lead sponsor: Klinikum St. Georg gGmbH
Sponsor class: OTHER
First posted: 2007-07-03
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with incurable illness

Brief summary: Euthanasia and assisted dying are of growing interest for patients with incurable diseases. The possible methods are widely discussed by patient-societies, physicians, lawyers, theologians and philosophers. During the last years several opinion-polls were conducted with healthy people or medical stuff, but no surveys were conducted to get the attitude of incurable ill patients.

The hypothesis of the investigators' study is: "Palliative Care Medicine is a better option for incurable ill patients than an assisted suicide."


Eligibility criteria: Inclusion Criteria:

* Age \>= 18 years
* Incurable illness
* Mental state thet allows to answer a questionnaire

Exclusion Criteria:

* Somnolence
* Low mental state
* Curable disease
* Depression with danger of acute suicide

Primary outcomes:
measure: Patients intention to assisted suicide
timeFrame: up to four weeks after beginning of palliative treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Leipzig
country: Germany
facility: Klinikum St. Georg gGmbH
state: Saxonia
Study officials:
affiliation: Klinikum St. Georg Leipzig, Clinics of Anesthesiology, Critical Care and Pain Therapy
name: Armin R Sablotzki, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Klinikum St. Georg Leipzig, Clinics of Anesthesiology, Critical Care and Pain Therapy
name: Matthias Thieme, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05163782: Validation of an Ankle Foot Orthosis With Anterior Support for Foot Drop
Official title: Validation of an Ankle Foot Orthosis With Anterior Support for Foot Drop
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Foot Drop
Lead sponsor: TOPMED
Sponsor class: OTHER
Collaborators: name: Turbomed Orthotics Inc.
name: Natural Sciences and Engineering Research Council, Canada
First posted: 2021-12-20
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this research is to compare the new ankle foot orthosis (AFO) with prior support developed by Turbomed, with the AFO with posterior support from Turbomed as well as two competing AFOs currently on the market.

With this research, we seek to answer the following questions:

* Is the new AFO as biomechanically efficient as the AFOs currently on the market?
* Is the new AFO more comfortable than the AFO currently on the market?
* Is the new AFO easier to put on and attach than the AFOs currently on the market?


Eligibility criteria: Inclusion Criteria:

* Foot drop following surgery or an accident (functional calf, without contracture and not spastic)
* Foot drop following a Cerebral Vascular Accident (with or without spasticity, mild to moderate)
* Ability to stand and walk alone without technical assistance
* Ability to communicate comfort/discomfort

Exclusion Criteria:

* Sore to one of the feet

Primary outcomes:
measure: Knee flexion angle during gait
timeFrame: At delivery
measure: Hip flexion angle during gait
timeFrame: At delivery
measure: Minimum foot clearance
timeFrame: At delivery
measure: Comfort of participants with orthosis
timeFrame: At delivery
measure: Easy to put on orthosis
timeFrame: At delivery
Secondary outcomes:
Other outcomes:
Locations:
city: Québec
country: Canada
facility: TOPMED
state: Quebec
Study officials:
affiliation: TOPMED
name: Edith Martin, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04037982: RCT Study on Safety of LPD and OPD in the Treatment of Periampullary Tumors
Official title: A Randomized Controlled Study on the Safety of Total Laparoscopy and Traditional Open Pancreaticoduodenectomy in the Treatment of Periampullary Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Periampullary Tumor
Complication
Death
Survival
Lead sponsor: Beijing Friendship Hospital
Sponsor class: OTHER
First posted: 2019-07-30
Enrollment: 102
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Pancreaticoduodenectomy (PD) is considered one of the most complex and dangerous procedures in general surgery. This procedure is the preferred surgical procedure for treating tumors around the ampulla. Traditional open pancreaticoduodenectomy (OPD) has brought great surgical trauma to patients while treating diseases. In 1994, Gagner et al first reported laparoscopic pancreaticoduodenectomy (LPD). With the development of laparoscopic techniques, the updating of devices, and the continuous accumulation of laparoscopic gastrointestinal surgery experience, the results of retrospective studies published show that there is no significant difference in safety between LPD and OPD. However, the results of the recently published RCT study show that the mortality associated with LPD complications is five times greater than that of OPD. At present, the security of LPD has been controversial. Therefore we conducted a prospective randomized controlled trial with a primary outcome of perioperative complications, providing evidence-based results for the safe and effective clinical development of LPD.


Eligibility criteria: Preoperative imaging diagnosis of periampullary tumor, or preoperative pathological diagnosis of periampullary tumor, preoperative evaluation can be performed pancreaticoduodenectomy; Serum bilirubin was less than 100 μ mol/L before operation; Sign a written informed consent form and agree to be randomly divided into groups for surgical treatment.

Primary outcomes:
measure: Incidence of complications
timeFrame: 30 days after operation
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Friendship Hospital, Capital medical University
Study officials:
References:
Clinical trial NCT07017582: The Effect of Bicarbonate Supplementation on Performance and Gastrointestinal Symptoms in Rugby Players.
Official title: Bicarbonate and Rugby
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Supplementation
Keywords: Bicarbonate
Rugby
Performance
Lead sponsor: Universidad de Burgos
Sponsor class: OTHER
Collaborators: name: Universidad Isabel I
First posted: 2025-06-12
Enrollment: 17
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objetive of the study was to determine whether sodium bicarbonate supplementation improves athletic performance and/or reduces fatigue in elite rugby players.

The participants were 17 elite rugby players. Half of the participants receive sodium bicarbonate (0.3 g/kg body weight), the other half receive a placebo (salt). Ingestion of the supplementation/placebo occured 90 minutes before high-intensity rugby-specific training Variables analysed were measure at baseline, prior to exercise, during exercise and after exercise.


Eligibility criteria: Inclusion Criteria:

* Male rugby players who were competing in the First Spanish National League (Division de Honor A) voluntarily agreed to participate in the study after attending an informative session

Exclusion Criteria:

* injury or illness on test day

Primary outcomes:
measure: Capillary blood lactate
timeFrame: At baseline (prior to supplementation), prior to exercise (immediately before beginning exercise protocol), after exercise (immediately after finishing exercise protocol).
Secondary outcomes:
measure: Countermovement jump
timeFrame: At baseline (prior to supplementation) and after exercise (immediately after finishing exercise protocol).
measure: Gastrointestinal (GI) symptoms
timeFrame: At baseline (before supplementation), prior to exercise (immediately before beginning exercise protocol), after exercise (immediately after finishing exercise protocol).
Other outcomes:
Locations:
city: Burgos
country: Spain
facility: Universidad de Burgos
Study officials:
References:
Clinical trial NCT01799382: Role of Rapid On-site Evaluation for Mutational Analysis of EBUS-TBNA Specimens
Official title: Mutational Analysis of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) Specimens in Patients With Advanced Non-small Cell Lung Cancer: a Randomized Trial of Rapid On-site Evaluation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Non-small Cell Lung Cancer
Lead sponsor: Maggiore Bellaria Hospital, Bologna
Sponsor class: OTHER
First posted: 2013-02-26
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of the study is to determine if rapid on-site evaluation of EBUS-TBNA samples can increase the percentage of patients with advanced non-squamous non-small cell lung cancer in whom both pathologic subtyping and mutational analysis are obtained.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Suspected hilar or mediastinal lymph node metastasis from lung cancer

Exclusion Criteria:

* Pregnancy
* Uncontrolled coagulopathy
* Refusal to sign informed consent

Primary outcomes:
measure: Mutational analysis of epidermal growth factor receptor (EGFR), K-ras, and ALK (anaplastic lymphoma kinase) genes
timeFrame: 18 months
Secondary outcomes:
measure: Diagnostic yield of EBUS-TBNA
timeFrame: 18 months
measure: Adequacy of EBUS-TBNA samples
timeFrame: 18 months
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: Maggiore Hospital
state: Emilia Romagna
Study officials:
affiliation: Maggiore Hospital, Bologna, Italy
name: Rocco Trisolini, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Trisolini R, Cancellieri A, Tinelli C, de Biase D, Valentini I, Casadei G, Paioli D, Ferrari F, Gordini G, Patelli M, Tallini G. Randomized Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration With and Without Rapid On-site Evaluation for Lung Cancer Genotyping. Chest. 2015 Dec;148(6):1430-1437. doi: 10.1378/chest.15-0583.
Clinical trial NCT00893282: Clinical Evaluation of BackStop in Patients Undergoing Intraureteric Stone Lithotripsy
Official title: A Randomized, Controlled, Prospective, Single Blind Clinical Evaluation of BackStop in Patients Undergoing Intraureteric Stone Lithotripsy.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Renal Calculi
Kidney Stones
Keywords: renal
calculi
kidney
stones
Lead sponsor: Pluromed, Inc.
Sponsor class: INDUSTRY
First posted: 2009-05-05
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this clinical study is to evaluate BackStop, a polymer-based device that is intended to be used during ureteroscopic lithotripsy to prevent retrograde stone migration. It is a water soluble polymer with reverse thermosensitive properties; the polymer exists as a liquid at low temperature (below 17 C) and rapidly transitions to a high viscosity gel at body temperature (i.e. in the ureter). BackStop is injected above the stones in the ureter and is intended to prevent retrograde migration of stones during ureteroscopic lithotripsy. Upon completion of the lithotripsy procedure, BackStop dissolves naturally or by irrigation.

The study hypothesis is that a greater proportion of patients will experience no retropulsion of a kidney stone when BackStop is used versus no anti-retropulsion device when undergoing intracorporeal lithotripsy.


Eligibility criteria: Inclusion Criteria:

* Patient with a solitary, radio-opaque ureteral stone in the proximal ureter.
* Clinical indication for treatment by ureteroscopic lithotripsy.
* Minimum 18 years old (or any institutional age limits for participation in clinical study).
* Patients must be willing and able to participate in any follow-up visits, as required.
* Patients must provide informed consent.

Exclusion Criteria:

-

Primary outcomes:
measure: Ability of BackStop™ to minimize migration stone fragments in the proximal ureter will and reported as "yes" or "no".
timeFrame: intra-operative
Secondary outcomes:
measure: Extent of residual fragments remaining in ureter at the follow-up visit 2 to 4 weeks post-procedure.
timeFrame: one month
measure: In the event that stone fragments migrate retrograde, there may be a need for the physician to employ additional procedures
timeFrame: one month
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: McGill University Health Center
state: Quebec
Study officials:
References:
Clinical trial NCT04404582: Clinical Characteristics for the Critical Ill Patients With Klebsiella Pneumoniae Infection
Official title: Analysis of the Clinical Characteristics for the Critical Ill Patients With Klebsiella Pneumoniae Infection: A Multi-center Research in the Intensive Care Units
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Drug Resistance
Lead sponsor: Fujian Provincial Hospital
Sponsor class: OTHER
First posted: 2020-05-27
Enrollment: 546
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult whose body fluid were sampled during ICU stay and Klebsiella pneumoniae was detected, followed by drug sensitivity test.

Brief summary: The detection of Klebsiella pneumoniae virulence gene and antibiotics resistance gene takes a long time and high cost with equipment requirements. Distinguishing the Klebsiella pneumoniae by gene were late for clinical treatment. Therefore, the investigators aim to study the clinical characteristics of critically ill patients with Klebsiella pneumoniae infection which expressed different drug sensitivity test results.

Detailed description: Clinical data of adult patients in integrated ICUs of 6 hospitals of Fujian Province China from January 2015 to July 2019 were collected, who had been examined for sputum, urine, blood, pleural effusion, ascites, cerebrospinal fluid and wound secretions and other body fluid samples. And the results showed that Klebsiella pneumoniae was positive, including demographic data, underlying disease status, drug sensitivity test, infection-related indicators, life support, prognostic indicators.

Eligibility criteria: Inclusion Criteria:

* Adult whose body fluid were sampled during ICU stay and Klebsiella pneumoniae was detected, followed by drug sensitivity test (including reporting the test results after the patient was transferred out of ICU or died).

Exclusion Criteria:

* Age were less than 18 years old;
* Patients stayed in ICU was less than 48 hours.

Primary outcomes:
measure: prognostic indicators
timeFrame: 30 day
measure: ICU stays
timeFrame: about a mouth
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: